WOMEN in Scotland with relapsed ovarian cancer will be offered a life-extending pill on NHS Scotland for the first time.
Campaigners described the decision to prescribe niraparib to eligible patients as a "gamechanger" in the fight against the disease, which claims the lives of around 350 women in Scotland every year.
The drug will be made available to women with advanced ovarian cancer which has returned, and who do not have the BRCA genetic mutation.
The Scottish Medicines Consortium said there were currently fewer satisfactory alternative treatments for this group of patients.
Niraparib - also known by the brand name Zejula - works by stopping cancer cells from repairing themselves, effectively crippling them.
It is part of a new family of cancer treatments known as PARP inhibitors.
Only two have been approved for use by the SMC before, but niraparib is the first to be made available to women with recurrent ovarian cancer on a mass scale since most patients - around 85% - do not have the BRCA mutation.
Carriers of the BRCA 1 and BRCA 2 mutation are at higher risk of developing ovarian cancer, but they already have access to another PARP inhibitor - olaparib - on NHS Scotland.
In clinical trials, women without the BRCA mutation who were given niraparib averaged just over nine months without the disease progressing compared to four months for the placebo.
When the disease returned, their average progression-free survival on niraparib was 18 and a half months compared to 15 and a half months for the placebo.
It can be taken easily at home as an oral daily tablet.
In Scotland, one woman dies every day from ovarian cancer and just 39 per cent of women diagnosed with ovarian cancer will survive for five years or more.
Annwen Jones, chief executive of Target Ovarian Cancer, said: “We know that with the right investment in new treatments, more women can and will survive this disease. Today is a critical first step in making that a reality.”
Catherine Clotworthy, 63, from Kilmaurs in East Ayrshire, has been taking niraparib for 10 months via an expanded access scheme.
She said: “When I was first diagnosed with ovarian cancer in 2014, I was so shocked – I’d been having problems with digestion and with my tummy for years but I never thought it could be cancer.
"The cancer is advanced, but last October I started taking niraparib - and now I can see a future for myself.
"I had such a fear of cancer – but now I have a chance to live with it. I believe all women living with this disease should have that, too.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here